NIDA Strategic Alliances for Medications Development Grant

The National Institute on Drug Abuse (NIDA) is offering a grant to facilitate the development of medications for treating Substance Use Disorders (SUDs). This grant aims to expedite the drug development process by forming strategic alliances with external organizations like academic institutions, pharmaceutical companies, and foundations. Funding of up to $2,000,000/year is available for projects with defined entry and exit points in the medications development pathway. The goal is to enhance the pace of medications development for SUDs by collaborating to advance compounds towards FDA approval and broaden clinical indications.

Opportunity ID: 240181

Apply

General Information

Document Type::	Grants Notice
Funding Opportunity Number::	PAR-13-334
Funding Opportunity Title::	Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01)
Opportunity Category::	Discretionary
Opportunity Category Explanation::
Funding Instrument Type::
Category of Funding Activity::	Education
Category Explanation::
Expected Number of Awards::
Assistance Listings Number(s)::	93.279 — Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement::	No
Version::	Synopsis 2
Posted Date::	Aug 19, 2013
Last Updated Date::	Aug 11, 2014
Original Closing Date for Applications::	Sep 07, 2016
Current Closing Date for Applications::	Sep 07, 2016
Archive Date::	Oct 08, 2016
Estimated Total Program Funding::
Award Ceiling::	$3,000,000
Award Floor::	$

Eligibility

Eligible Applicants::

Independent school districts

Additional Information on Eligibility::

Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name::	National Institutes of Health
Description::	NIDA grant-funded research programs aiming to develop medications for the treatment of Substance Use Disorders (SUDs) are often hindered by a lack of both human and financial resources.Drug development is a lengthy process that requires a wide range of skill sets.Consequently, individual grantees with the necessary expertise in one area of medications development are often unable to advance a project through the next stage because of a lack of real world experience in the development process and/or the financial resources to advance a medication through the development pipeline in an acceptable timeframe. The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outsideorganizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses.Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat SUDs move through the drug development process.Both the term (up to three years) and budget (up to $2,000,000/year in direct costs) of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding.Project aims can range from the development of a new molecular entity to the expansion of an existing medications clinical indication(s). Each project must have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process.It is hoped that support for these collaborations will accelerate the rate of medications development for Substance Use Disorders.
Link to Additional Information::
Grantor Contact Information::	If you have difficulty accessing the full announcement electronically, please contact:

Version History

Version	Modification Description	Updated Date
Synopsis 2	This funding opportunity has had its budgetary limits increased per NOT-DA-14-027.	Aug 11, 2014
Synopsis 1

Package Status

Below are CLOSED Opportunity Package(s) no longer available for this Funding Opportunity:

Package No: 1

Assistance Listings:	93.279
Competition ID:	FORMS-C
Competition Title:	Forms-C
Opportunity Package ID:	PKG00183510
Opening Date:	Feb 27, 2014
Closing Date:	May 17, 2016
Agency Contact Information::	eRA Commons Help Desk
Who Can Apply::	Organization Applicants
mendatory_forms	SF424 (R & R) [V2.0] PHS 398 Research Plan [V2.0] PHS 398 Cover Page Supplement [V2.0] Research and Related Senior/Key Person Profile (Expanded) [V2.0] Research And Related Other Project Information [V1.3] Project/Performance Site Location(s) [V2.0]
optional_forms	R & R Subaward Budget Attachment(s) Form 5 YR 30 ATT [V1.3] Planned Enrollment Report [V1.0] PHS 398 Cumulative Inclusion Enrollment Report [V1.0] PHS 398 Modular Budget [V1.2] Research & Related Budget [V1.3]

Package No: 2